THE SCHEDULE 13G

Company

CytomX Therapeutics, Inc.

Filed

March 6, 2020

Accession Number

0000921895-20-000679

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →